ERAS-0015(JYP0015) is a tricomplex inhibitor of panRAS(ON) targeting of active RAS, it binds to Cyclophilin A (CYPA) to form a high-affinity complex that sterically occludes RAS–effector interactions. It exhibits potential for research in RAS-mutant solid tumors.
More Information Supplier PageOlomorasib (KRAS G12C inhibitor 19, LY3537982) is a potent and highly selective second-generation inhibitor of GDP-bound KRAS G12C, with the potential to treat patients with advanced solid tumors carrying the KRAS G12C mutation.
More Information Supplier PageOlomorasib (KRAS G12C inhibitor 19, LY3537982) is a potent and highly selective second-generation inhibitor of GDP-bound KRAS G12C, with the potential to treat patients with advanced solid tumors carrying the KRAS G12C mutation.
More Information Supplier PageOlomorasib (KRAS G12C inhibitor 19, LY3537982) is a potent and highly selective second-generation inhibitor of GDP-bound KRAS G12C, with the potential to treat patients with advanced solid tumors carrying the KRAS G12C mutation.
More Information Supplier PageOlomorasib (KRAS G12C inhibitor 19, LY3537982) is a potent and highly selective second-generation inhibitor of GDP-bound KRAS G12C, with the potential to treat patients with advanced solid tumors carrying the KRAS G12C mutation.
More Information Supplier PageNSC2805 is a potent inhibitor of WWP2 ubiquitin ligase with an IC50 of 0.38 μM. It is used in cancer research for studying WWP2-associated pathways.
More Information Supplier PageNSC2805 is a potent inhibitor of WWP2 ubiquitin ligase with an IC50 of 0.38 μM. It is used in cancer research for studying WWP2-associated pathways.
More Information Supplier PagePDK4-IN-1 hydrochloride is an anthraquinone-derived, orally active allosteric inhibitor of PDK4 with an IC50 of 84 nM, exhibiting anticancer activity by regulating cell proliferation, transformation, and apoptosis. It also exhibit antidiabeti and anti-allergic activity.
More Information Supplier PageNSC2805 is a potent inhibitor of WWP2 ubiquitin ligase with an IC50 of 0.38 μM. It is used in cancer research for studying WWP2-associated pathways.
More Information Supplier PageNSC2805 is a potent inhibitor of WWP2 ubiquitin ligase with an IC50 of 0.38 μM. It is used in cancer research for studying WWP2-associated pathways.
More Information Supplier Page
